Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 8Terminated 4Recruiting 3Active not recruiting 3Withdrawn 2Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Sarcoma 1Penile Neoplasms 1PD-L1 Positive Mutation Tumor 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Chronic-Phase 1Hodgkin Disease 1Hemangiosarcoma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Sunitinib 14aldesleukin 10Bevacizumab 8pembrolizumab 7Nivolumab 7pazopanib 5Axitinib 5atezolizumab 4Interferon-alpha 4sintilimab 3durvalumab 3Sorafenib 3Everolimus 3Cyclophosphamide 3Chemotherapy, Adjuvant 3toripalimab 2sargramostim 2olaparib 2lenvatinib 2fludarabine phosphate 2camrelizumab 2avelumab 2Neoadjuvant Therapy 2Laparoscopy 2Ipilimumab 2Interferon alpha-2 2Immunohistochemistry 2Immune Checkpoint Inhibitors 2Gene Expression Profiling 2Fluorouracil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Renal Cell × avelumab × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03341845 2018-05-21

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

The Netherlands Cancer Institute

Phase 2 Unknown
40 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡